TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05976789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound therapy using low-level background sound
Description: This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote counseling using HAT-Online
Description: This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
Study: NCT06090006

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Circumcision screening
Description: Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Risky behaviours
Description: Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HIV testing
Description: HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: STI (CT, NG, TV) testing
Description: Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
Study: NCT05976789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound therapy using successive approximations
Description: This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
Study: NCT05810701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive geriatric assessment and individualised physical training
Description: Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
Study: NCT05281406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg daily or reduced dose 40 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study: NCT06090006

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Immunization screening
Description: Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual impairment screening
Description: Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hearing screening
Description: HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Physical impairment screening
Description: Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Uncontrolled epilepsy screening
Description: Questions on experience of convulsions followed by referral to specialist if indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pre-hypertension screening
Description: Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
Study: NCT04885855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG
Description: Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG
Description: Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravidasvir 200mg
Description: Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
Study: NCT06274229

Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.

Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.

Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.

Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.

Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
Study: NCT05281406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study: NCT06050200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVE
Description: The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVD
Description: The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALPPS
Description: The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane).
Study: NCT06226272

Intervention type: DEVICE
Intervention: Spinal Fusion
Description: Cervical Spinal Fusion

Intervention type: DEVICE
Intervention: Spinal Fusion
Description: Thoracic / Lumbar Spinal Fusion

Intervention type: DEVICE
Intervention: Spinal Deformities Correction
Description: Spinal Deformities Correction
Study: NCT06352814

Intervention type: OTHER
Intervention: Activities-based locomotor training (physical therapy)
Description: AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
Study: NCT05789329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Guilt Reduction Therapy
Description: behavioral intervention aimed to reduce trauma-related guilt and shame

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: behavioral intervention aimed at reducing PTSD symptoms
Study: NCT04664205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: One session of high intensity interval exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: One session of high intensity interval exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: One session of high intensity interval exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise
Description: One session of calorically matched moderate intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise
Description: One session of calorically matched moderate intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise
Description: One session of calorically matched moderate intensity exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No exercise, resting measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No exercise, resting measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No exercise, resting measures
Study: NCT05312996

Intervention type: OTHER
Group type: OTHER
Intervention: Heart Rate Variability
Description: Caretaker Heart Rate Variability ECG wrist monitor and chest patch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability
Description: Caretaker Heart Rate Variability ECG wrist monitor and chest patch.

Intervention type: OTHER
Group type: OTHER
Intervention: Galvanic Skin Response (Biopac)
Description: Galvanic Skin Response- measuring autonomic response-via perspiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galvanic Skin Response (Biopac)
Description: Galvanic Skin Response- measuring autonomic response-via perspiration
Study: NCT04886726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uhCG/EGF
Description: PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Study: NCT06312917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
Study: NCT05564572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Health Status Assessment
Description: Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
Study: NCT06148870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia Control Lens-1 (MCL1)
Description: The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia Control Lens-1 (MCL1)
Description: The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia Control Lens-2 (MCL2)
Description: The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia Control Lens-2 (MCL2)
Description: The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
Study: NCT05944835

Intervention type: OTHER
Intervention: Analyzed on the post-operative scanner
Description: Analyzed on the post-operative scanner
Study: NCT05913362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVUS based ultralow contrast PCI
Description: IVUS based ultralow contrast PCI
Study: NCT03939104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine+amodiaquine
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine+placebo
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.
Study: NCT06460753

Intervention type: DIAGNOSTIC_TEST
Intervention: CT of the chest organs, blood biochemical parameters
Description: Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.
Study: NCT03939104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine+piperaquine
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine+placebo
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets.
Study: NCT05093582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
Study: NCT06001879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation in basic life support training (SBLST)
Description: The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation, and clinical simulation training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment by using an AHA-BLS 2020 brochure
Description: The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test
Study: NCT05413798

Intervention type: OTHER
Group type: OTHER
Intervention: Urine HPV testing
Description: Human papillomavirus (HPV) testing in urine sample.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-collected cervicovaginal specimen
Description: Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.

Intervention type: OTHER
Group type: OTHER
Intervention: Provider-collected cervical samples
Description: Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
Study: NCT06088693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Standard Therapy
Description: Acupuncture Needle Insertion with Electroacupuncture machine.
Study: NCT05584098

Intervention type: OTHER
Group type: OTHER
Intervention: qSOFA and MEWS
Description: qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
Study: NCT05542082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHILLS Procedure
Description: Cryotherapy
Study: NCT05010278

Intervention type: PROCEDURE
Intervention: Latarjet
Description: Patients followed up 6 months after a Latarjet procedure
Study: NCT06069804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The TR group
Description: Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The R group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Study: NCT06196827

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX101
Description: Subretinal Administration
Study: NCT06545305

Intervention type: PROCEDURE
Intervention: Lensectomy and vitrectomy
Description: Corrections
Study: NCT05812950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GST
Description: Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: Outpatient eating disorder treatment (20-40 weekly individual sessions)